162 related articles for article (PubMed ID: 35889402)
1. The Inhibitory Potential of 2'-dihalo Ribonucleotides against HCV: Molecular Docking, Molecular Simulations, MM-BPSA, and DFT Studies.
Khalil A; El-Khouly AS; Elkaeed EB; Eissa IH
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889402
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV.
Elfiky AA; Ismail A
Life Sci; 2019 Dec; 238():116958. PubMed ID: 31628915
[TBL] [Abstract][Full Text] [Related]
3. Combined 3D-QSAR, molecular docking, molecular dynamics simulation, and binding free energy calculation studies on the 5-hydroxy-2H-pyridazin-3-one derivatives as HCV NS5B polymerase inhibitors.
Yu H; Fang Y; Lu X; Liu Y; Zhang H
Chem Biol Drug Des; 2014 Jan; 83(1):89-105. PubMed ID: 23941500
[TBL] [Abstract][Full Text] [Related]
4. Novel Guanosine Derivatives as Anti-HCV NS5b Polymerase: A QSAR and Molecular Docking Study.
Elfiky AA
Med Chem; 2019; 15(2):130-137. PubMed ID: 30324891
[TBL] [Abstract][Full Text] [Related]
5. Screening of hepatitis C NS5B polymerase inhibitors containing benzothiadiazine core: a steered molecular dynamics.
Nutho B; Meeprasert A; Chulapa M; Kungwan N; Rungrotmongkol T
J Biomol Struct Dyn; 2017 Jun; 35(8):1743-1757. PubMed ID: 27236925
[TBL] [Abstract][Full Text] [Related]
6. Structural insights into NS5B protein of novel equine hepaciviruses and pegiviruses complexed with polymerase inhibitors.
de Albuquerque PPLF; Santos LHS; Antunes D; Caffarena ER; Figueiredo AS
Virus Res; 2020 Mar; 278():197867. PubMed ID: 31972246
[TBL] [Abstract][Full Text] [Related]
7. Repositioning of RdRp Inhibitors Against HCV NS5B Polymerase Utilizing Structure-Based Molecular Docking.
Tarannum H; Nandi S
Comb Chem High Throughput Screen; 2022; 25(4):702-719. PubMed ID: 33475069
[TBL] [Abstract][Full Text] [Related]
8. Probing the "fingers" domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations.
Manjula S; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2019 Jun; 37(9):2440-2456. PubMed ID: 30047829
[TBL] [Abstract][Full Text] [Related]
9. Molecular Docking and Pharmacoinformatics Studies Reveal Potential Phytochemicals Against HCV NS5B Polymerase.
Khalid H; Ashfaq UA
Comb Chem High Throughput Screen; 2022; 25(2):335-346. PubMed ID: 33371844
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling and residue interaction network studies on the mechanism of binding and resistance of the HCV NS5B polymerase mutants to VX-222 and ANA598.
Xue W; Jiao P; Liu H; Yao X
Antiviral Res; 2014 Apr; 104():40-51. PubMed ID: 24462692
[TBL] [Abstract][Full Text] [Related]
11. An Exploration of the Inhibitory Mechanism of Rationally Screened Benzofuran-1,3,4-Oxadiazoles and-1,2,4-Triazoles as Inhibitors of NS5B RdRp Hepatitis C Virus through Pharmacoinformatic Approaches.
Irfan A; Faisal S; Ahmad S; Saif MJ; Zahoor AF; Khan SG; Javid J; Al-Hussain SA; Muhammed MT; Zaki MEA
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002085
[TBL] [Abstract][Full Text] [Related]
12. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
Elhefnawi M; ElGamacy M; Fares M
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of Taraxacum officinale against HCV NS5B polymerase: In-vitro and In silico study.
Rehman S; Ijaz B; Fatima N; Muhammad SA; Riazuddin S
Biomed Pharmacother; 2016 Oct; 83():881-891. PubMed ID: 27513212
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel Hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase.
Khalid H; Landry KB; Ijaz B; Ashfaq UA; Ahmed M; Kanwal A; Froeyen M; Mirza MU
Infect Genet Evol; 2020 Oct; 84():104371. PubMed ID: 32485331
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and SAR optimization of diketo acid pharmacophore for HCV NS5B polymerase inhibition.
Bhatt A; Gurukumar KR; Basu A; Patel MR; Kaushik-Basu N; Talele TT
Eur J Med Chem; 2011 Oct; 46(10):5138-45. PubMed ID: 21893371
[TBL] [Abstract][Full Text] [Related]
16. Accounting for target flexibility and water molecules by docking to ensembles of target structures: the HCV NS5B palm site I inhibitors case study.
Barreca ML; Iraci N; Manfroni G; Gaetani R; Guercini C; Sabatini S; Tabarrini O; Cecchetti V
J Chem Inf Model; 2014 Feb; 54(2):481-97. PubMed ID: 23952658
[TBL] [Abstract][Full Text] [Related]
17. Anti-hepatitis-C virus activity and QSAR study of certain thiazolidinone and thiazolotriazine derivatives as potential NS5B polymerase inhibitors.
Hassan GS; Georgey HH; Mohammed EZ; Omar FA
Eur J Med Chem; 2019 Dec; 184():111747. PubMed ID: 31604164
[TBL] [Abstract][Full Text] [Related]
18. Detailed computational study of the active site of the hepatitis C viral RNA polymerase to aid novel drug design.
Barakat KH; Law J; Prunotto A; Magee WC; Evans DH; Tyrrell DL; Tuszynski J; Houghton M
J Chem Inf Model; 2013 Nov; 53(11):3031-43. PubMed ID: 24116674
[TBL] [Abstract][Full Text] [Related]
19. Novel 4-thiazolidinones as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase.
Çakir G; Küçükgüzel İ; Guhamazumder R; Tatar E; Manvar D; Basu A; Patel BA; Zia J; Talele TT; Kaushik-Basu N
Arch Pharm (Weinheim); 2015 Jan; 348(1):10-22. PubMed ID: 25449674
[TBL] [Abstract][Full Text] [Related]
20. 2-Heteroarylimino-5-arylidene-4-thiazolidinones as a new class of non-nucleoside inhibitors of HCV NS5B polymerase.
Küçükgüzel I; Satılmış G; Gurukumar KR; Basu A; Tatar E; Nichols DB; Talele TT; Kaushik-Basu N
Eur J Med Chem; 2013 Nov; 69():931-41. PubMed ID: 24161679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
